Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
0.00%
)
Bitcoin
69,251.07
(
0.53%
)
News Focus
News Focus
Post# of 257268
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 167668

Monday, 10/07/2013 1:47:18 PM

Monday, October 07, 2013 1:47:18 PM

Post# of 257268
Good point re the different prevalence of GT1a vs GT1b in different countries; however, the percentages are not unduly lopsided. Among all GT1 patients, if one assumes 2/3 of treated patients will be GT1a in the US and 2/3 of treated patients will be GT1b in Japan and the EU, that’s probably close enough for modeling purposes.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today